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Table 1.
Mean vessel diameters from preoperative baseline to 27 weeks post-operative f-AVG placement.

Program: Nephrology
Type: Original Research
Background: Arteriovenous fistulas
(AVF) are the preferred vascular access
in hemodialysis (HD) patients. Smaller
pre-operative vessel diameters decrease
subsequent AVF patency and often leads
to avoidance of AVF for initial HD access.
Among patients with marginal vessel
diameters, arteriovenous grafts (AVG),
including forearm arteriovenous grafts
(fAVG), may be a preferred alternative.
Prior studies demonstrated proximal vessel
remodeling after fAVG creation, but timing
of these changes is unknown. In this pilot
study, we aimed to determine the timing and
degree of vessel remodeling following fAVG
creation.
Methods: We prospectively evaluated the
basilic and cephalic veins, and brachial artery
in 10 patients undergoing fAVG placement.
Vessel diameter was assessed by ultrasound
prior to surgery and at 1, 4, 12 and 27 weeks
post- fAVG, and compared across the
respective time points. The brachial artery
was measured near the antecubital fossa,

Baseline (cm)

1 Week (cm)

4 Weeks (cm)

12 Weeks (cm)

27 Weeks (cm)

Antecubital

0.29

0.49

0.58

0.57

0.53

Mid Upper Arm

0.36

0.59

0.62

0.65

0.62

Prox Upper Arm

0.37

0.74

0.72

0.65

0.64

Antecubital

0.30

0.37

0.34

0.45

0.50

Mid Upper Arm

0.22

0.31

0.33

0.37

0.45

Prox Upper Arm

0.29

0.32

0.35

0.32

0.40

0.41

0.49

0.50

0.53

0.49

Basilic Vein

Cephalic Vein

Brachial Artery

while the cephalic and basilic vein were
measured at the antecubital fossa (AC), mid
upper-arm (MID), and proximal upper-arm
(UP).
Results: Basilic vein diameter increased at
week one across all sites and continued to
increase through week 12. The change in the
cephalic vein was less than the basilic vein,
but the AC location increased from baseline to

week 12. The increase in mean brachial artery
diameter reached significance at week 12.
Conclusion: In our pilot cohort, we observed
substantial increases in basilic vein diameter,
and cephalic vein diameter following fAVG
creation. The rapid increase in size of upper
arm vessels may improve the success of
secondary upper arm fistula formation. 
https://doi.org/10.32873/unmc.dc.gmerj.4.1.039
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Background: Eye surgeries are one of the
most commonly performed procedures
worldwide. Improved surgical techniques and
instrumentation have significantly decreased
the number of complications and provided the
opportunity to reduce the need for topical eye
medications. We aim to examine the potential
financial benefits to the VA health care system
after implementing a reduced peri-operative
eye drop schedule.
Methods: After reviewing the costs of
various peri-operative eye drops obtained
through the Veteran’s Administration Hospital,
analysis was conducted on the potential
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risks and benefits of each medication. It
was determined that dexamethasone 0.1%,
neomycin sulfate 3.5mg/mL and polymyxin
B sulfate 10,000 U/mL (Maxitrol®) can
act to prevent post-operative complications
while allowing for simpler instruction to
patients, which would reduce confusion and
potentially improve medication compliance.
Ketorolac 0.5% would only be used in
patients at increased risk of developing
cystoid macular edema (previous history
of diabetic retinopathy or uveitis). A costanalysis was then performed for the current
and proposed drop regimens. A pre- and postimplementation survey will be given to the
ancillary staff and physicians to determine the
effects of the implementation.

(Table 1). A cost reduction of 58.6% to 81.5%
was calculated depending on the optional
addition of Ketorolac.
Conclusion: A consolidated peri-operative
drop regimen for routine ophthalmic surgery
confers a substantial cost benefit while
reducing eye drop burden to the patient and
simplifying patient instruction. 
https://doi.org/10.32873/unmc.dc.gmerj.4.1.040

Results: The costs of the current and reduced
peri-operative drop regimen were calculated

Graduate Medical Education Research Journal

*Names in bold type indicate presenting author.
Table 1.
Total costs for the Omaha VA Hospital of current peri-operative drop regimen compared with total costs for the reduced peri-operative drop regimen.
Current Peri-operative Drop Regimen
Medication

Instructions

Application

Phase of care

Cost

Lidocaine gel 3.5%

Once. Prior to surgery, administered by pre-op nurses.

Topical anesthesia

Pre-operative

$2.71

Cyclopentolate 1%

The night before surgery use 2 times, 5 minutes apart just before bedtime.
The morning of surgery use 3 times 5 minutes apart just prior to leaving
home for the hospital.

Pupillary dilation

Pre-operative

$1.10

Ketorolac 0.5%

QID. Start 2 days prior to surgery and continue for 2 weeks after surgery.

Prevention of cystoid
macular edema

Pre- and postoperative

$4.69

Prednisolone acetate 1%

QID. Start after surgery and decrease by 1 drop each week for 4 weeks.

Control of intraocular
inflammation

Post-operative

$11.52

Polytrim 0.1%:

QID. Start 2 days prior to surgery and continue after surgery for 1 week.

Prevention of infection

Pre- and postoperative

$0.01

Total cost per surgery

$20.03

Total cost per year (800 surgeries)

$16,024.00

Reduced Peri-operative Drop Regimen
Medication

Instructions

Application

Phase of care

Cost

Cyclopentolate 1%

The morning of surgery just prior to leaving home for the hospital.

Pupillary dilation

Pre-operative

$1.10

Maxitrol

TID. Start after surgery for two weeks, then stop.

Prevention of infection
and inflammation

Post- operative

$2.61

Ketorolac 0.5%

TID. For patients with diabetic retinopathy or uveitis. Use for 2 weeks after
surgery, then stop.

Prevention of cystoid
macular edema

Pre- and postoperative

$4.69

Total cost per surgery

$8.40

Total cost per year with ketorolac

$6,720.00

Total cost per year without ketorolac

$2,968.00
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Background: Randomized controlled trials
have demonstrated that administration of
methadone during lumbar spinal fusion
surgery decreases pain scores and narcotic
consumption in the immediate post-operative
period. The purpose of this study is to report
patient and surgical characteristics in cases of
lumbar spinal fusion where methadone was
used as an adjunct analgesic on the day of
surgery.
Methods: This is a single institution
retrospective review of patients undergoing
lumbar posterior spinal fusion (PSF) or
transforaminal lumbar interbody fusion
(TLIF) over a two-year period from 7/1/2019
– 7/1/2021. Patients were identified using the
CPT codes for PSF and TLIF. The electronic
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medical records of these patients were
queried to identify patients who had received
methadone on the day of their surgery. Patient
characteristics that were collected include
opioid consumption within 6 months prior to
surgery, history of prior lumbar spine surgery,
age, body mass index (BMI), sex, smoking
status, ASA class, and opioid consumption
status at three weeks and six months postoperatively. Operative data collected included
surgeon’s details, adjunctive use of ketamine,
type of procedure, and estimated blood loss
(EBL).
Results: A total of 527 patients were
identified of whom 29 (5.5%) received
methadone on the day of surgery. The male/
female ratio was 15:14 with an average age
of 63 years and an average BMI of 31.5. Six
patients (21%) were current smokers during
the time of their surgery and 11 patients
(38%) were using opioids pre-operatively.
Most patients were categorized as ASA class
3 (24/29, 83%), and the rest were ASA class

2. Notably, 18 patients (62%) had a history
of prior lumbar spine surgery. The average
number of levels fused was 3.3 (SD 2.4,
range 1-10), with an average EBL of 422 mL.
Overall, the number of patients using opioids
at three weeks and 6 months post-operatively
were 19 (66%) and 5 (17%) respectively.
Conclusion: A small percentage of lumbar
fusion procedures received methadone
analgesia at our institution. Most patients who
received methadone analgesia had a history
of prior lumbar spine surgery and were
undergoing multi-level surgery. The main
limitation of this study is its retrospective
nature. Future research should include
comparative studies to assess the differences
in outcomes between patients who receive
methadone versus those who do not. 
https://doi.org/10.32873/unmc.dc.gmerj.4.1.041
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